Case Report

Primary antiphospholipid antibody syndrome presenting as acute superior mesenteric vein thrombosis

Vignesh N. C.*, Manivannan D., Maniselvi S., Kannan R.

Department of General Surgery, Madras Medical College, Chennai, Tamil Nadu, India

Received: 04 April 2021
Revised: 09 May 2021
Accepted: 11 May 2021

*Correspondence:
Dr. Vignesh N. C.,
E-mail: nc.vignesh94@gmail.com

ABSTRACT

Antiphospholipid antibody syndrome (APS) is an autoantibody mediated thrombophilia characterised by recurrent arterial or venous thrombosis and/or pregnancy morbidity. APS presenting as thrombosis in mesenteric venous system is relatively uncommon (10%). Here, we present a case of primary APS presenting as acute superior mesenteric vein (SMV) thrombosis in a 38-year-old female. She was admitted with the complaints of abdominal pain and constipation for five days. Her abdomen was distended with sluggish bowel sounds. Her abdominal contrast enhanced computed tomography revealed thrombosis of SMV, splenic vein and portal vein. She was initially kept on conservative management and started on anticoagulants. Her coagulation work-up revealed that she was positive for anticardiolipin antibody and therefore, the diagnosis of APS was made. She was continued on conservative management and anticoagulants. On the tenth day of admission, after starting oral diet, she developed severe abdominal pain and abdominal signs of peritonitis. She was then taken up for emergency laparotomy. Intraoperatively; there was 100 cm of gangrenous ileal segment, about 60 cm from ileocecal junction and 160 cm from duodenojejunal flexure. The gangrenous ileal segment was resected and a double barrel ileostomy was constructed. She had an uneventful postoperative recovery and was started on lifelong anticoagulants.

Keywords: Antiphospholipid antibody, Mesenteric ischemia, Venous thrombosis, Anticoagulant

INTRODUCTION

Acute mesenteric ischemia is a severe life-threatening gastrointestinal emergency, accounting for 1 in 1000 hospital admissions worldwide, with a mortality of 40%.1,2 It is characterised by decreased mesenteric blood supply to visceral organs of gastrointestinal tract. It is classified into four different types based on underlying cause: non-occlusive, arterial thrombosis, arterial embolic and venous thrombosis. Amongst these, venous thrombosis is the least common cause. Mesenteric venous thrombosis (MVT) in the setting of APS is uncommon. Once the diagnosis of MVT is made, a search for underlying cause is a must. This helps us determine the duration of anticoagulation, in order to prevent recurrent thrombosis in such patients. The duration of anticoagulation varies depending on the underlying conditions associated with MVT such as inflammation, malignancy and thrombophilia like APS, as in our patient. Local inflammation is considered temporary and potentially treatable, so patients are anticoagulated for 3 to 6 months. In case of underlying malignancy or thrombophilia, lifelong anticoagulation is required, to prevent recurrent thrombosis in such patients.

CASE REPORT

This is a case of 38 years aged female who presented with 5 days history of abdominal pain, nausea and vomiting. She had previous history of two spontaneous
abortions. Contrast enhanced computed tomography (CECT) abdomen revealed thrombosis of SMV, portal vein, splenic vein, poorly enhancing bowel wall with thickening of jejunum (Figure 1), superior mesenteric artery (SMA) was normal and there was no evidence of pneumatosis intestinalis. Patient was diagnosed as a case of mesenteric vasculitis, due to SMV thrombosis and it was confirmed by abdominal angiogram. She was managed conservatively and started on intravenous heparin. Her serum antinuclear antibody was negative. Anticardiolipin antibody was positive. Given the finding of primary APS with SMV thrombosis, she was continued on anticoagulants. On tenth day after admission, three days after starting diet, she developed severe abdominal pain and abdominal signs of peritonitis. She was then, taken up for emergency laparotomy. Ileal gangrene was noted, for about 100 cm, which was 60 cm from ileocaecal junction and 160 cm from duodenojejunal junction (Figure 2 and 3). We proceeded with resection of gangrenous ileal segment, proximal end ileostomy and distal mucous fistula was done. Post-operatively, she was started on low molecular weight heparin (LMWH) and later changed to oral warfarin. She was advised to continue lifelong oral warfarin, to prevent recurrent thrombotic attacks.

**DISCUSSION**

Most patients with acute mesenteric vein thrombosis (MVT) have predisposing risk factors like inflammatory process, thrombophilia or malignancies.\(^1,2\) Rarely, autoimmune thrombophilia like APS, can cause acute MVT. The diagnosis of APS can be made with classical clinical findings and laboratory evidence of antiphospholipid antibodies (aPL) like lupus anticoagulant or IgG or IgM antibodies to cardiolipin or beta 2-glycoprotein.\(^3,4\) Reports of seronegative APS with clinically significant thrombosis and atypical IgA antibodies to cardiolipin or beta 2-glycoprotein exist.\(^5\) - \(^9\) Current guidelines recommend lifelong anticoagulation with vitamin K antagonists (VKA) like warfarin to prevent thrombosis and thrombotic events. Only ten cases of acute MVT caused by APS are described in literature, all involving SMV and were treated with VKAs.\(^10\) - \(^19\) In APS, aPL antibodies induce a hypercoagulable state by promoting platelet aggregation and activation, synthesis of proinflammatory cytokines like interleukin-6, tumour necrosis factor alpha, and increased expression of platelet membrane glycoprotein IIB/IIIA by endothelial cells.\(^20\) When collaterals are also involved by the thrombotic process, lethal complications like infarction, necrosis, perforation of bowel and sepsis occur. In acute MVT, bowel rest, intravenous fluids, analgesia and anticoagulation are important to prevent thrombus extension and to promote recanalisation.\(^21\) - \(^23\) Anticoagulation with parenteral heparin, as a bridge to oral VKAs like warfarin was used for acute MVT caused by APS. LMWH is the preferred parenteral anticoagulant over un-fractionated heparin (UFH).\(^24\) Anticoagulation with VKAs can be erratic, so the therapeutic range between international normalised ratio (INR) of 2.0-3.0 is required to prevent recurrent thrombosis. In refractory APS or when there are contraindications to oral anticoagulants, LMWH is used for long term anticoagulation.\(^25\)
CONCLUSION
With a diagnosis of acute SMV thrombosis, a search for hypercoagulable state is indicated. This will help determine the duration of anticoagulation and prevent recurrent thrombosis. A high level of suspicion is needed to diagnose acute MVT, when the patient presents with vague abdominal pain and hematochezia, because thrombosis of mesenteric vessels is rare and lethal if left undiagnosed. An early detection on acute MVT, diagnosis of APS and initiation of anticoagulation is necessary to prevent progression of thrombosis and complications.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

Cite this article as: Vignesh NC, Manivannan D, Maniselvi S, Kannan R. Primary antiphospholipid antibody syndrome presenting as acute superior mesenteric vein thrombosis. Int Surg J 2021;8:1901-3.